
Arrhythmic risk stratification in heart failure: Time for the next step?
Author(s) -
Gatzoulis Konstantinos A.,
Sideris Antonios,
Kanoupakis Emmanuel,
Sideris Skevos,
Nikolaou Nikolaos,
Antoniou ChristosKonstantinos,
Kolettis Theofilos M.
Publication year - 2017
Publication title -
annals of noninvasive electrocardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 48
eISSN - 1542-474X
pISSN - 1082-720X
DOI - 10.1111/anec.12430
Subject(s) - medicine , risk stratification , cardiology , heart failure , stratification (seeds) , seed dormancy , botany , germination , dormancy , biology
Background Primary prevention of sudden cardiac death by means of implantable cardioverter‐defibrillators constitutes the holy grail of arrhythmology. However, current risk stratification algorithms lead to suboptimal outcomes, by both allocating ICD s to patients not deriving any meaningful survival benefit and withholding them from those erroneously considered as low‐risk for arrhythmic mortality. Methods In the present review article we will attempt to present shortcomings of contemporary guidelines regarding sudden death prevention in ischemic and dilated cardiomyopathy patients and present available data suggesting encouraging results following implementation of multifactorial approaches, by using multiple modalities, both noninvasive and invasive. Invasive electrophysiological testing, namely programmed ventricular stimulation, will be discussed in greater length to highlight both its potential usefulness and currently ongoing multicenter studies aiming to provide evidence necessary to make the next step in sudden death risk stratification. Results Promising findings have been reported by multiple study groups regarding novel strategies for both negative selection of low and positive selection of relatively preserved ejection fraction patients as candidates for ICD implantation. Conclusions The era of ejection fraction as the sole risk stratifier for arrhythmic risk in heart failure appears to be drawing to an end, especially if current underway large studies validate previous findings.